EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors Meeting Abstract
| Authors: | Balar, A. V.; McGregor, B. A.; Rosenberg, J. E.; van der Heijden, M. S.; Park, S. H.; Lee, J. L.; Harrison, M. R.; Heath, E. I.; Stein, M. N.; Loriot, Y.; Necchi, A.; Steinberg, J. L.; Liang, S. Y.; Kim, E.; Trowbridge, J.; Campbell, M. S.; Petrylak, D. P.; Yu, E. Y. |
| Abstract Title: | EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors |
| Meeting Title: | 2021 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2021 Feb 11-13 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-02-20 |
| Language: | English |
| ACCESSION: | WOS:000636801500397 |
| DOI: | 10.1200/JCO.2021.39.6_suppl.394 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 394 -- Source: Wos |
